Roughly, they can be divided into two directions: one is to identify inhibitors targeting HSP70 based on its cancer-promoting role and the other is to develop cancer vaccines in which HSP70 serves as an adjuvant based on its immunostimulatory effect. This evidence concerns the gene HSPA1A and cancer.